1.42

3.65% 0.05

After Hours: 1.43 0.01 +0.70%

Coherus Oncology Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Oncology Inc stock is traded at $1.42, with a volume of 304.11K. It is up +3.65% in the last 24 hours and down -4.05% over the past month. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Previous Close:

$1.37

Open:

$1.38

24h Volume:

304.11K

Relative Volume:

0.31

Market Cap:

$219.39M

Revenue:

$46.88M

Net Income/Loss:

$-172.66M

P/E Ratio:

-1.1396

EPS:

-1.2461

Net Cash Flow:

$-170.57M

1W Performance:

+0.71%

1M Performance:

-4.05%

6M Performance:

-19.32%

1Y Performance:

+8.40%

1-Day Range:

$1.38

$1.435

1-Week Range:

$1.30

$1.435

52-Week Range:

$1.09

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Name

Coherus Oncology Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

145

Twitter

@coherus_bio

Next Earnings Date

2026-08-05

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Oncology Inc	1.42	203.94M	46.88M	-172.66M	-170.57M	-1.2461
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-26	Initiated	Oppenheimer	Outperform
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Oncology Inc Stock (CHRS) Latest News

Sep 04, 2026

Coherus BioSciences stock reacts to BlackRock stake and latest oncology focus - AD HOC NEWS

Sep 04, 2026

Sep 01, 2026

CHRS Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2.59% Share GainPost-Earnings Reaction - vinanet.vn

Sep 01, 2026

Aug 31, 2026

Coherus to Participate in Upcoming Investor Conferences - Yahoo Finance

Aug 31, 2026

Aug 28, 2026

Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners - TradingView

Aug 28, 2026

Aug 24, 2026

Coherus (CHRS) Quarter in Focus: The Bottom-Line Figure Beats Its Comparison at the Close; Closing Reaction: Shares Finish 4.23% Down for the Current SessionEarnings Growth Analysis - vinanet.vn

Aug 24, 2026

Aug 19, 2026

Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development - Seeking Alpha

Aug 19, 2026

Coherus (CHRS) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Market Reaction: Shares Finish 16.52% UpEarnings Power Value - vinanet.vn

Aug 19, 2026

Aug 17, 2026

Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com India

Aug 17, 2026

CHRS Looks 10.6% Overvalued on GF Value™ - GuruFocus

Aug 17, 2026

Coherus Oncology Secures $55M Term Loan, Extends Debt Maturity to 2031 - Minichart

Aug 17, 2026

Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com

Aug 17, 2026

Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - tradingview.com

Aug 17, 2026

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire

Aug 17, 2026

Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan

Aug 17, 2026

Coherus Oncology, Inc., Coherus Intermediate Corp, Surface Oncology, LLC, and InteKrin Therapeutics Inc., Enter into Loan and Security Agreement - marketscreener.com

Aug 17, 2026

Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria

Aug 07, 2026

Aug 06, 2026

H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 06, 2026

Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 06, 2026

Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Synthetic Long - vinanet.vn

Aug 06, 2026